The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
Open accessAbstract
Apolipoprotein E (apoE) is critical in the modulation of cholesterol and phospholipid transport between cells of different types. Human apoE is a polymorphic protein with three common alleles, APO epsilon 2, APO epsilon 3, and APO epsilon 4. ApoE4 is associated with sporadic and late-onset familial Alzheimer disease (AD). Gene dose was shown to have an effect on risk of developing AD, age of onset, accumulation of senile plaques in the brain, and reduction of choline acetyltransferase (ChAT) activity in the hippocampus of AD subjects. To characterize the possible impact of the apoE4 allele on cholinergic markers in AD, we examined the effect of apoE4 allele copy number on pre- and postsynaptic markers of cholinergic activity. ApoE4 allele copy number showed an inverse relationship with residual brain ChAT activity and nicotinic receptor binding sites in both the hippocampal formation and the temporal cortex of AD subjects. AD cases lacking the apoE4 allele showed ChAT activities close or within age-matched normal control values. The effect of the apoE4 allele on cholinomimetic drug responsiveness was assessed next in a group (n = 40) of AD patients who completed a double-blind, 30-week clinical trial of the cholinesterase inhibitor tacrine. Results showed that > 80% of apoE4-negative AD patients showed marked improvement after 30 weeks as measured by the AD assessment scale (ADAS), whereas 60% of apoE4 carriers had ADAS scores that were worse compared to baseline. These results strongly support the concept that apoE4 plays a crucial role in the cholinergic dysfunction associated with AD and may be a prognostic indicator of poor response to therapy with acetylcholinesterase inhibitors in AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES
KARNOVSKY, M. J., & ROOTS, L. (1964) · Journal of Histochemistry & Cytochemistry · doi:10.1177/12.3.219 · Cited by 3,367
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Self-citationKnapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Lipoprotein receptors and cholesterol homeostasis
Mahley, R. W., & Innerarity, T. L. (1983) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(83)90001-1 · Cited by 755
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693
Apolipoprotein E in animal models of CNS injury and in alzheimer's disease
Poirier, J. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90156-2 · Cited by 639
Self-citation
Cited by
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Medical and Ethical Consequences of the Human Genome Project
Collins, F. S. (1991) · The Journal of Clinical Ethics · doi:10.1086/jce199102411 · Cited by 666
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Medical and Societal Consequences of the Human Genome Project
Collins, F. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410106 · Cited by 578
Ott, A., Slooter, A., Hofman, A., van Harskamp, F., Witteman, J., Van Broeckhoven, C., van Duijn, C., & Breteler, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07541-7 · Cited by 535
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
The use of single-nucleotide polymorphism maps in pharmacogenomics
McCarthy, J. J., & Hilfiker, R. (2000) · Nature Biotechnology · doi:10.1038/75360 · Cited by 434
Single nucleotide polymorphisms and the future of genetic epidemiology
Schork, N. J., Fallin, D., & Lanchbury, J. S. (2000) · Clinical Genetics · doi:10.1034/j.1399-0004.2000.580402.x · Cited by 412
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 384
The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics
Hedgecoe, A., & Martin, P. (2003) · Social Studies of Science · doi:10.1177/03063127030333002 · Cited by 340
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Cholinergic dysfunction in diseases with Lewy bodies
Tiraboschi, P., Hansen, L. A., Alford, M., Sabbagh, M. N., Schoos, B., Masliah, E., Thal, L. J., & Corey-Bloom, J. (2000) · Neurology · doi:10.1212/wnl.54.2.407 · Cited by 328
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?
McPartland, J. M., & Russo, E. B. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n03_08 · Cited by 321
Arendt, T., Schindler, C., Brückner, M. K., Eschrich, K., Bigl, V., Zedlick, D., & Marcova, L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00516.1997 · Cited by 319
Law, A. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00051-5 · Cited by 314
Buckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 308
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
Vitamin E and Alzheimer disease: the basis for additional clinical trials
Grundman, M. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.630s · Cited by 264
Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment
Fleisher, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.953 · Cited by 258
Saunders, A., Hulette, C., Welsh-Bohmer, K., Schmechel, D., Crain, B., Burke, Jr., Alberts, M., Strittmatter, W., Breitner, J., Rosenberg, C., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01251-2 · Cited by 253
Huang, Y., Weisgraber, K. H., Mucke, L., & Mahley, R. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:189 · Cited by 242
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
“…with APOE e3/e4 heterozygotes or APOE e3 homozygous patients (Rebeck et al. 1993; Schmechel et al. 1993; Zubenko et al. 1994; Gearing et al. 1995; Hyman et al. 1995; Nagy et al. 1995; Oyama et al. 1995; Polvikoski et al. 1995; Beffert and Poirier 1996; Gomez-Isla et al. 1996; Olichney et al. 1996).”
BackgroundResultButtini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“However, biochemical and neuropathological alterations of the cholinergic system have been detected primarily in later stages of the disease, and their modification by apoE isoforms remains controversial (Poirier et al., 1995; Soininen et al., 1995; Allen et al., 1997; Arendt et al., 1997; Salehi et al., 1998; Gilmor…”
BackgroundNeuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease
Chaudhari, K. S., Tiwari, N. R., Tiwari, R. R., & Sharma, R. S. (2017) · Annals of Neurosciences · doi:10.1159/000475900 · Cited by 167
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Hypometabolism as a therapeutic target in Alzheimer's disease
Costantini, L. C., Barr, L. J., Vogel, J. L., & Henderson, S. T. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s16 · Cited by 162
“In a study of tacrine, 80% of ApoE4-negative AD patients improved relative to baseline, whereas 60% of ApoE4-positive patients declined [55].”
BackgroundRole of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Meng, X.-F., Yu, J.-T., Wang, H.-F., Tan, M.-S., Wang, C., Tan, C.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140954 · Cited by 150
“Previous findings that APOE4 carriers with AD have fewer nicotinic receptor binding sites and lower activity of choline acetyltransferase compared with non-carriers [40, 41] have supported this hypothesis.”
Court, J. A., Lloyd, S., Thomas, N., Piggott, M. A., Marshall, E. F., Morris, C. M., Lamb, H., Perry, R. H., Johnson, M., & Perry, E. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00088-8 · Cited by 135
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
White, F., Nicoll, J. A. R., Roses, A. D., & Horsburgh, K. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0401 · Cited by 128
Grouselle, D., Winsky-Sommerer, R., David, J. P., Delacourte, A., Dournaud, P., & Epelbaum, J. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00698-3 · Cited by 92
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1–42
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Blaine Stine, W., Manelli, A., Sullivan, P., Pasternak, J. F., & LaDu, M. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.011 · Cited by 82
“ApoE isoforms may also differentially modulate the expression of nicotinic acetylcholine receptors (Poirier et al., 1995), receptors that have been shown to modulate hippocampal LTP (Ji et al., 2001) and for which Ah has recently been shown to act as a ligand (Wang et al., 2000).”
Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice
Krzywkowski, P., Ghribi, O., Gagné, J., Chabot, C., Kar, S., Rochford, J., Massicotte, G., & Poirier, J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00061-5 · Cited by 74
Self-citationMaloney, B., Ge, Y., Alley, G. M., & Lahiri, D. K. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04831.x · Cited by 63
Self-citationShanmugaratnam, J., Berg, E., Kimerer, L., Johnson, R. J., Amaratunga, A., Schreiber, B. M., & Fine, R. E. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00176-9 · Cited by 68
Chun, J. T., Wang, L., Pasinetti, G. M., Finch, C. E., & Zlokovic, B. V. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7052 · Cited by 67
Yoon, B.-K., Kim, D. K., Kang, Y., Kim, J.-W., Shin, M.-H., & Na, D. L. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04666-6 · Cited by 35
Pharmacogenetics‐Based New Therapeutic Concepts
Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., et al. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033458 · Cited by 33
Lai, M. K. P., Tsang, S. W. Y., Garcia-Alloza, M., Minger, S. L., Nicoll, J. A. R., Esiri, M. M., Wong, P. T.-H., Chen, C. P. L.-H., Ramírez, M. J., & Francis, P. T. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.016 · Cited by 29
Cerebrospinal fluid apolipoprotein E concentration decreases after seizure
Wang, L., Han, Y., Chen, D., Xiao, Z., Xi, Z., Xiao, F., & Wang, X. (2010) · Seizure · doi:10.1016/j.seizure.2009.12.001 · Cited by 23
APOE ε4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics
Kaufer, D., & Gandy, S. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c6784a · Cited by 21
Metadata
- Authors
- Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-12-19
- Volume
- 92
- Issue
- 26
- Pages
- 12260-12264
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2072150523
- Cited by
- 595
- References
- 39
- FWCI
- 21.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.